Cloak and dagger in the avoidance of immune surveillance

Current Opinion in Genetics and Development

Volumn 10, Issue 1, 2000, Pages 114-119

  Pinkoski, Michael J ^a   Green, Douglas R ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FAS ANTIGEN; FAS LIGAND;

APOPTOSIS; CELL COUNT; IMMUNOSURVEILLANCE; INFLAMMATION; LYMPHOCYTE CLONE; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR; TUMOR IMMUNOLOGY;

EID: 0034000977     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(99)00048-9     Document Type: Review

References (51)

1. Pinkoski M.J., Green D.R. Fas ligand, death gene. Cell Death Differ. 6:1999;1174-1180.
2. Hunig T., Schimpl A. Systemic autoimmune disease as a consequence of defective lymphocyte death. Curr Opin Immunol. 9:1997;826-830.
3. Green D.R. Apoptotic pathways: the roads to ruin. Cell. 94:1998;695-698.
4. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308.
5. Wolf B.B., Green D.R. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem. 274:1999;20049-20052.
6. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
7. Walker P.R., Saas P., Dietrich P.Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol. 10:1998;564-572.
8. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today. 20:1999;46-52.
9. French L.E., Hahne M., Viard I., Radlgruber G., Zanone R., Becker K., Muller C., Tschopp J. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol. 133:1996;335-343.
10. Owen-Schaub L.B., van Golen K.L., Hill L.L., Price J.E. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med. 188:1998;1717-1723. This paper provides evidence of involvement of host CD95L in surveillance of CD95+ melanoma metastases. Downregulation of this system provides the necessary cloak for immune avoidance and contributes to successful metastatic outgrowth.
11. Peli J., Schroter M., Rudaz C., Hahne M., Meyer C., Reichmann E., Tschopp J. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J. 18:1999;1824-1831. Downregulation of CD95 in transformed cells may provide a means to evade clearance by effector lymphocytes. This study demonstrates that downregulation of CD95 expression can be mediated by Ras, thus providing evidence for a dual purpose of Ras: oncogenic transformation and immune avoidance.
12. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev. 8:1998;49-54.
13. Hueber A.O., Zornig M., Lyon D., Suda T., Nagata S., Evan G.I. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 278:1997;1305-1309.
14. Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell. 3:1999;565-577. In an elegant study with localised activation of c-Myc in keratinocytes, this paper describes the ability to generate a pre-neoplastic lesion by forced activation of c-Myc - an effect that is transient and reversible when c-Myc is deactivated.
15. Hill L.L., Ouhtit A., Loughlin S.M., Kripke M.L., Ananthaswamy H.N., Owen Schaub L.B. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science. 285:1999;898-900. An intriguing study showing the involvement of CD95L in shedding of skin following sunburn. This raises the possibility that sunburn and subsequent shedding of skin is a protective mechanism against skin cancer to remove damaged keratinocytes. A debate over the potential positive effects of sunburn versus sunscreen has ensued.
16. ••] this paper describes how induced CD95L also plays a role in establishing a transient site resembling immune privilege following damage by ultraviolet radiation. These data also support the notion that CD95-CD95L interactions are required for ultraviolet radiation induced immune suppression by a mechanism involving antigen presentation processes.
17. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
18. Bennett M., Macdonald K., Chan S.W., Luzio J.P., Simari R., Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 282:1998;290-293. A new mechanism to control sensitivity to death mediated through surface CD95. p53 stimulates display of CD95 on the cell surface from an intracellular pool of CD95 protein. p53-dependent trafficking of CD95 to the cell surface renders a cell susceptible to CD95-induced death without requirement for de novo RNA or protein synthesis. Presumably, disruption of the process could conceivably result in avoidance of CD95L-mediated immune surveillance.
19. Soengas M.S., Alarcon R.M., Yoshida H., Giaccia A.J., Hakem R., Mak T.W., Lowe S.W. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 284:1999;156-159. APAF-1 and caspase-9 are key components of the post-mitochondrial death machinery therefore it is unsurprising that double knockout mice for these genes result in an impaired ability to apoptose. This report shows that mutation of APAF-1 and/or caspase-9 can facilitate oncogenic transformation and may be important in human tumours.
20. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., Huang A., Donahue C.J., Sherwood S.W., Baldwin D.T.et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 396:1998;699-703. The title pretty much says it all. A new molecule implicated in immune avoidance by inhibiting CD95-CD95L interactions. Expression of a novel decoy receptor, DcR3, by malignancies is seen as an effective means to avoid being removed by CD95-CD95L mediated immune surveillance.
21. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:1994;969-976.
22. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314-317.
23. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y., Strober W., Lenardo M.J., Puck J.M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:1995;935-946.
24. Wu J., Wilson J., He J., Xiang L., Schur P.H., Mountz J.D. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 98:1996;1107-1113.
25. Wang J., Zheng L., Lobito A., Chan F.K., Dale J., Sneller M., Yao X., Puck J.M., Straus S.E., Lenardo M.J. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 98:1999;47-58. The first report of a caspase mutation associated with a human disease. It inludes interesting data showing the involvement of a dominant negative caspase-10 acting at the unlikely level of caspase-8.
26. -/- mouse embryonic fibroblasts, this paper describes the importance of PTEN phosphatase to properly regulate the death program initiated by a number of death stimuli. The authors claim that PTEN functions as a 'gatekeeper' tumour suppressor gene in the same manner as p53, Rb, and APC.
27. Haas-Kogan D., Shalev N., Wong M., Mills G., Yount G., Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 8:1998;1195-1198. This paper draws a link between the lack of PTEN phosphatase activity with an increase in protein kinase B activity and its association with glioblastoma. On the basis of the high incidence of PTEN mutations in glioblastoma and prostate cancers, the authors suggest that dysregulation of the PI3-kinase pathway is a major mediator of oncogenesis.
28. -/- mouse as an in vivo model system in which to study tumour progression.
29. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science. 282:1998;1318-1321.
30. Maehama T., Dixon J.E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9:1999;125-128.
31. Leevers S.J., Vanhaesebroeck B., Waterfield M.D. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol. 11:1999;219-225.
32. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 96:1999;4240-4245.
33. +/-) mice developed lethal autoimmune disorder as a result of impaired CD95 signaling which is required for clonal deletion of activated lymphocytes.
34. Dhein J., Walczak H., Baumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:1995;438-441.
35. Ju S.T., Panka D.J., Cui H., Ettinger R., el-Khatib M., Sherr D.H., Stanger B.Z., Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:1995;444-448.
36. Brunner T., Mogil R.J., LaFace D., Yoo N.J., Mahboubi A., Echeverri F., Martin S.J., Force W.R., Lynch D.H., Ware C.F., Green D.R. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:1995;441-444.
37. Genestier L., Kasibhatla S., Brunner T., Green D.R. Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J Exp Med. 189:1999;231-239.
38. Hildeman D.A., Mitchell T., Teague T.K., Henson P., Day B.J., Kappler J., Marrack P.C. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity. 10:1999;735-744. The studies here demonstrate that lymphocytes activated in vivo have a higher propensity to undergo apoptosis in culture ex vivo and that reactive oxygen species appear to mediate this process. The authors propose that this is a physiologically relevant mediator of AICD that is driven by elevated levels of ROS in active lymphocytes because of their heightened metabolic state.
39. Bonfoco E., Stuart P.M., Brunner T., Lin T., Griffith T.S., Gao Y., Nakajima H., Henkart P.A., Ferguson T.A., Green D.R. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity. 9:1998;711-720. This paper is the first demonstration that inducible CD95L expression by non-lymphoid tissue assists in the removal of activated peripheral lymphocytes, giving rise to the notion of 'inducible immune privilege' and its contribution to peripheral deletion.
40. Green D.R., Ware C.F. Fas-ligand: privilege and peril. Proc Natl Acad Sci USA. 94:1997;5986-5990.
41. Ferguson T.A., Griffith T.S. A vision of cell death: insights into immune privilege. Immunol Rev. 156:1997;167-184.
42. Chen J.J., Sun Y., Nabel G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 282:1998;1714-1717. This is an intriguing study showing that CD95L contributes to a pro-inflammatory response by transplanted cells and that these effects are moderated in the presence of TGF-β. It is not surprising that CD95L does not always guarantee survival of a transplanted graft and these studies show that TGF-β (and conceivably other cytokines as well) given at the site of transplant may improve success of a graft.
43. Allison J., Georgiou H.M., Strasser A., Vaux D.L. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA. 94:1997;3943-3947.
44. Takeuchi T., Ueki T., Nishimatsu H., Kajiwara T., Ishida T., Jishage K., Ueda O., Suzuki H., Li B., Moriyama N., Kitamura T. Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol. 162:1999;518-522.
45. Kang S.M., Hoffmann A., Le D., Springer M.L., Stock P.G., Blau H.M. Immune response and myoblasts that express Fas ligand. Science. 278:1997;1322-1324.
46. Gao Y., Herndon J.M., Zhang H., Griffith T.S., Ferguson T.A. Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis. J Exp Med. 188:1998;887-896. These studies outline some of the requirements for CD95L to maintain immune privilege status by virtue of differential cytokine expression. Notably, IL10 production by apoptotic cells resulted in the skewing of neighbouring lymphocytes to the anti-inflammatory Th2 subtypes, whereas in the absence of IL10, the Th1 subset was favoured with potentially inflammatory effects.
47. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 4:1998;31-36. The authors present a model to explain the protection of bystander cells in the vicinity of activated cytotoxic lymphocytes, in which soluble CD95L is produced by the CTL. In this model, only cells making physical contact with membrane bound CD95L on the CTL would be deleted.
48. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 187:1998;1205-1213.
49. Mitsiades N., Poulaki V., Kotoula V., Leone A., Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol. 153:1998;1947-1956.
50. Ottonello L., Tortolina G., Amelotti M., Dallegri F. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol. 162:1999;3601-3606. The findings in these studies support the notion of a pro-inflammatory effect of CD95L. The authors demonstrate that soluble CD95L can attract neutrophils which contributes to inflammation. This finding provides insights into a possible mechanism to explain earlier observations that CD95L-bearing grafts may mediate rejection.
51. Liles W.C., Kiener P.A., Ledbetter J.A., Aruffo A., Klebanoff S.J. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med. 184:1996;429-440.